Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
AWH

AWH - Aspira Women's Health Inc. Stock Price, Fair Value and News

1.95USD+0.09 (+4.84%)Market Closed

Market Summary

AWH
USD1.95+0.09
Market Closed
4.84%

AWH Alerts

  • 1 major insider buys recently.

AWH Stock Price

View Fullscreen

AWH RSI Chart

AWH Valuation

Market Cap

23.2M

Price/Earnings (Trailing)

-1.57

Price/Sales (Trailing)

2.58

EV/EBITDA

-1.71

Price/Free Cashflow

-2.92

AWH Price/Sales (Trailing)

AWH Profitability

EBT Margin

-208.82%

Return on Equity

1.1K%

Return on Assets

-205.76%

Free Cashflow Yield

-34.19%

AWH Fundamentals

AWH Revenue

Revenue (TTM)

9.0M

Rev. Growth (Yr)

-7.04%

Rev. Growth (Qtr)

1.08%

AWH Earnings

Earnings (TTM)

-14.7M

Earnings Growth (Yr)

29.63%

Earnings Growth (Qtr)

-49.85%

Breaking Down AWH Revenue

Last 7 days

-10.6%

Last 30 days

-35.4%

Last 90 days

-49.5%

Trailing 12 Months

-38.4%

How does AWH drawdown profile look like?

AWH Financial Health

Current Ratio

1.16

Debt/Equity

-0.99

Debt/Cashflow

-5.85

AWH Investor Care

Shares Dilution (1Y)

48.37%

Diluted EPS (TTM)

-1.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20249.0M000
20238.6M9.0M9.2M9.2M
20227.2M7.5M7.9M8.2M
20214.9M6.0M6.4M6.8M
20205.0M4.6M4.5M4.7M
20193.2M3.6M4.2M4.5M
20181.5M2.0M2.5M3.1M
2017477.0K632.0K787.0K942.0K
20161.7M1.9M2.2M322.0K
20153.2M3.4M3.4M2.2M
20142.5M2.5M2.5M2.5M
20132.1M2.1M2.1M2.6M
20121.8M1.8M1.8M2.1M
20111.4M1.5M1.7M1.9M
20100001.2M

Tracking the Latest Insider Buys and Sells of Aspira Women's Health Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 31, 2024
sandford nicole
bought
22,973
2.42
9,493
chief executive officer
Jan 26, 2024
sandford nicole
bought
-
-
2,400
president & ceo
Dec 06, 2023
merchant minh hoang
sold
-3,302
3.37
-980
secretary & general counsel
Dec 06, 2023
sandford nicole
bought
16,800
3.36
5,000
president & ceo
Nov 17, 2023
hombeck torsten
acquired
-
-
30,000
chief financial officer
Nov 17, 2023
merchant minh hoang
acquired
-
-
10,000
secretary & general counsel
Sep 08, 2023
hombeck torsten
bought
9,657
4.3
2,246
chief financial officer
Aug 29, 2023
sandford nicole
acquired
-
-
26,467
president & ceo
Aug 29, 2023
sandford nicole
acquired
-
-
26,367
president and ceo
Aug 28, 2023
fralick celeste rachelle
acquired
-
-
13,252
-

1–10 of 50

Which funds bought or sold AWH recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 16, 2024
B. Riley Wealth Advisors, Inc.
reduced
-30.1
-59,829
672,005
0.02%
May 15, 2024
STATE STREET CORP
unchanged
-
-17,884
56,572
-%
May 15, 2024
MORGAN STANLEY
added
6.51
-1,770
7,508
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
added
0.59
-28,068
90,998
-%
May 15, 2024
Royal Bank of Canada
reduced
-98.48
-38,000
-
-%
May 15, 2024
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO
sold off
-100
-2,011
-
-%
May 15, 2024
Squarepoint Ops LLC
added
65.56
16,169
78,858
-%
May 15, 2024
ARMISTICE CAPITAL, LLC
new
-
3,586,700
3,586,700
0.05%
May 15, 2024
Northeast Financial Consultants Inc
unchanged
-
-22,967
72,652
-%
May 15, 2024
Tower Research Capital LLC (TRC)
added
84.87
3,078
10,683
-%

1–10 of 32

Are Funds Buying or Selling AWH?

Are funds buying AWH calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AWH
No. of Funds

Unveiling Aspira Women's Health Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 08, 2024
schultz eric adam
4.41%
543,998
SC 13G/A
Dec 26, 2023
schultz eric adam
263%
543,998
SC 13G
Jul 26, 2023
schuler jack w
18.7%
1,883,656
SC 13D/A
Feb 15, 2023
seamark capital lp
5.1%
-
SC 13G/A
Aug 29, 2022
schuler jack w
20.8%
25,885,120
SC 13D/A
Feb 16, 2022
seamark capital lp
5.0%
-
SC 13G/A
Feb 14, 2022
drysdale robert h
-
0
SC 13G
Jan 13, 2022
sharman tanya schuler
5.3%
5,943,881
SC 13D/A
Dec 30, 2021
schuler tino hans
4.3%
4,829,019
SC 13D/A
Dec 30, 2021
schuler henri george
8.2%
9,207,779
SC 13D/A

Recent SEC filings of Aspira Women's Health Inc.

View All Filings
Date Filed Form Type Document
Jun 07, 2024
8-K
Current Report
Jun 03, 2024
4
Insider Trading
May 15, 2024
10-Q
Quarterly Report
May 15, 2024
8-K
Current Report
May 14, 2024
4
Insider Trading
May 14, 2024
4
Insider Trading
May 14, 2024
8-K
Current Report
May 10, 2024
DEFA14A
DEFA14A
May 06, 2024
4
Insider Trading
Apr 26, 2024
424B5
Prospectus Filed

Peers (Alternatives to Aspira Women's Health Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
196.0B
23.7B
5.17% 9.67%
44.52
8.26
-8.94% -35.91%
42.5B
3.7B
2.24% 9.78%
49.01
11.4
8.57% 23.94%
38.9B
6.6B
-9.88% 11.43%
31.28
5.89
-6.38% -8.07%
15.4B
9.3B
-1.39% 1.55%
18.23
1.66
-3.29% 6.68%
13.8B
1.2B
8.97% 122.00%
-37.84
11.44
39.26% 33.08%
12.5B
2.0B
3.72% 84.36%
40.03
6.37
25.57% 21.62%
11.0B
4.1B
-6.38% 2.81%
24.78
2.68
0.49% -10.45%
MID-CAP
7.8B
2.5B
-24.30% -55.03%
-32.37
3.07
15.21% 53.51%
3.9B
603.7M
32.67% -15.43%
-8.45
6.45
25.21% 30.68%
3.7B
929.2M
32.48% -13.74%
2.4K
3.97
28.93% 111.61%
SMALL-CAP
796.4M
275.1M
2.07% 82.89%
-4.35
2.89
-13.93% -126.97%
82.0M
31.1M
-2.54% -87.84%
-1.06
2.63
0.95% 19.75%
23.2M
9.0M
-35.42% -38.41%
-1.57
2.58
4.46% 45.80%
492.4K
5.5M
-83.77% -62.12%
-0.04
0.09
-68.52% -143.74%
183.8K
-
-50.00% -94.83%
-0.01
0.01
- -

Aspira Women's Health Inc. News

Latest updates
Simply Wall St7 hours ago
Yahoo Lifestyle UK03 May 202402:11 pm

Aspira Women's Health Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue1.1%2,1532,1302,2172,4912,3162,1532,0722,0661,8931,8511,6661,7991,4961,4461,2397461,2201,3081,2851,142803
Gross Profit-0.4%1,2141,2191,3071,5501,1861,2401,1569669611,014749696603231432153420516336234109
Operating Expenses10.6%5,9245,3545,4235,8717,4666,3319,7369,18610,2089,96010,4408,7686,4896,3054,7133,9794,2203,9204,1864,5393,828
  S&GA Expenses8.4%1,8891,7431,7021,7722,5952,8883,9503,5804,4974,8775,0834,0183,1082,8432,1521,7332,1152,0762,4252,7802,364
  R&D Expenses-15.9%9061,0779986931,2671,0022,1571,4101,3481,4531,5181,471872734595380395244340225209
EBITDA Margin-0.4%-2.07*-2.06*-2.05*-2.08*-2.18*-2.30*-2.40*-2.53*-2.62*-2.77*-2.94*-3.15*-3.82*-4.05*-------
Interest Expenses-350.0%-5.002.0012.008.0026.0027.0018.00-10.00-18.00-13.00-14.003.00-24.00-4.005.001.008.0020.0034.00-2.007.00
EBT Margin0%-2.09*-2.09*-2.08*-2.12*-2.22*-2.34*-2.43*-2.56*-2.65*-2.81*-2.98*-3.20*-3.88*-4.11*-------
Net Income-49.9%-4,629-3,089-4,706-2,317-6,578-4,591-7,783-8,243-9,268-8,961-9,707-7,074-5,920-6,081-4,287-3,831-3,706-3,387-3,820-4,314-3,716
Net Income Margin10.1%-1.64*-1.82*-1.98*-2.35*-3.16*-3.65*-4.35*-4.84*-4.86*-4.65*-4.49*-3.91*-4.08*-3.85*-------
Free Cashflow56.4%-4,451-10,2003,3213,413-5,714-7,150-7,568-6,327-10,255-7,679-8,019-6,585-5,296-4,979-------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets14.4%7,1646,2628,6627,72011,49617,37323,94224,01630,86141,07948,04755,82962,29719,60521,26513,09110,35313,82816,53318,1528,254
  Current Assets15.9%6,1225,2807,5726,86210,52816,30922,97622,95629,80040,00547,18854,90761,37318,60320,25112,6909,98613,41016,05017,5657,576
    Cash Equivalents31.4%3,4132,5975,1004,2467,53513,55720,55120,48026,85537,43044,87052,99359,36916,63118,83610,9358,13211,70314,63616,1796,174
  Inventory4.0%23622730127230231628019118917413710171.0030.0045.0066.0063.0025.0029.0090.0098.00
  Net PPE-20.6%131165221261305368417438480464498546533583593360318353399472531
Liabilities-1.2%8,5278,6279,3218,24810,66910,39412,7649,8949,11710,9079,5438,9919,9729,8866,7155,8245,0515,0904,7064,7864,617
  Current Liabilities3.4%5,2935,1195,1625,3745,9115,5277,2977,0446,1397,8406,4095,7916,1486,0004,6154,1993,9853,9783,5373,5613,336
  Short Term Borrowings-37.9%41667077.00306535764-260519779-204408611476587194303192191190
  Long Term Debt-5.8%1,3471,4301,2171,3342,2042,3152,4262,5362,6462,7182,7682,8182,7183,4771,6781,6151,0501,0991,1481,1961,244
    LT Debt, Current50.0%249166378259442403343283223201200199201645---193---
    LT Debt, Non Current-5.8%1,3471,4301,2171,3342,2042,3152,4262,5362,6462,7182,7682,8182,7183,4771,6781,6151,0501,0991,1481,1961,244
Shareholder's Equity42.4%-1,363-2,365--8276,97911,17814,12221,74430,17238,50446,83852,3259,71914,5507,2675,3028,73811,82713,3663,637
  Retained Earnings-0.9%-522,932-518,303-515,214-507,282-504,965-501,613-497,022-489,239-480,996-471,728-462,767-453,060-445,986-440,066-433,985-429,698-425,867-422,161-418,774-414,954-410,640
  Additional Paid-In Capital1.1%521,557515,927514,544506,745505,784508,584508,192503,249502,628501,893501,159499,786498,199449,680448,431436,864431,072430,802430,504428,226414,202
Shares Outstanding16.0%12,34410,64510,2878,4738,3138,3068,2967,4837,4767,4767,3947,3547,2446,975-------
Float----17,677---50,184---477,546---290,268---47,232-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations56.5%-4,431-10,1883,3213,417-5,706-7,076-7,515-6,304-10,173-7,649-8,001-6,490-5,255-4,756-3,067-3,410-3,501-2,871-3,442-3,544-3,108
  Share Based Compensation-14.2%3624226812253964205466108385901,1781,282489427411441269300296413184
Cashflow From Investing-66.7%-20.00-12.00--4.00-8.00-74.00-53.00-23.00-82.00-30.00-18.00-95.00-41.00-223-144-100-23.00-12.00-39.00-34.00-48.00
Cashflow From Financing448.3%5,2699614,176134-55.00-94.007,639-48.00-70.00-11.0014620948,0342,77411,1126,313-47.00-50.001,93813,583-30.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

AWH Income Statement

2024-03-31
Condensed Consolidated Statements Of Operations (unaudited) - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenue:  
Revenue$ 2,153,000$ 2,316,000
Cost of revenue:  
Cost of revenue939,0001,130,000
Gross profit1,214,0001,186,000
Operating expenses:  
Research and development906,0001,267,000
Sales and marketing1,889,0002,595,000
General and administrative3,129,0003,604,000
Total operating expenses5,924,0007,466,000
Loss from operations(4,710,000)(6,280,000)
Other income (expense), net:  
Change in fair value of warrant liabilities251,000(24,000)
Interest (expense) income, net(5,000)26,000
Other expense, net(165,000)(300,000)
Total other income (expense), net81,000(298,000)
Net loss$ (4,629,000)$ (6,578,000)
Net loss per share - basic$ (0.39)$ (0.79)
Net loss per share - diluted$ (0.39)$ (0.79)
Weighted average common shares used to compute basic net loss per common share11,846,0758,313,091
Weighted average common shares used to compute diluted net loss per common share11,846,0758,313,091
Product [Member]  
Revenue:  
Revenue$ 2,153,000$ 2,315,000
Cost of revenue:  
Cost of revenue$ 939,0001,130,000
Genetics [Member]  
Revenue:  
Revenue $ 1,000

AWH Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 3,413,000$ 2,597,000
Accounts receivable, net of reserves of $2 and $15, as of March 31, 2024 and December 31, 2023, respectively1,531,0001,459,000
Prepaid expenses and other current assets942,000997,000
Inventories236,000227,000
Total current assets6,122,0005,280,000
Property and equipment, net131,000165,000
Right-of-use assets620,000528,000
Restricted cash260,000258,000
Other assets31,00031,000
Total assets7,164,0006,262,000
Current liabilities:  
Accounts payable1,643,0001,261,000
Accrued liabilities2,797,0002,863,000
Current portion of long-term debt249,000166,000
Short-term debt416,000670,000
Current maturities of lease liabilities188,000159,000
Total current liabilities5,293,0005,119,000
Non-current liabilities:  
Long-term debt1,347,0001,430,000
Non-current maturities of lease liabilities487,000427,000
Warrant liabilities1,400,0001,651,000
Total liabilities8,527,0008,627,000
Commitments and contingencies (Note 4)
Stockholders' deficit:  
Common stock, par value $0.001 per share, 200,000,000 and 150,000,000 shares authorized at March 31, 2024 and December 31, 2023, respectively; 12,344,104 and 10,645,049 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively12,00011,000
Additional paid-in capital521,557,000515,927,000
Accumulated deficit(522,932,000)(518,303,000)
Total stockholders' deficit(1,363,000)(2,365,000)
Total liabilities and stockholders' deficit$ 7,164,000$ 6,262,000
AWH
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering. Its product pipeline includes OvaWatch, a non-invasive blood-based risk assessment test to determine ovarian cancer risk for patients with an adnexal mass; and Endocheck, an in-development non-invasive blood test designed as an aid in the identification of endometriosis for patients with suspected endometriosis earlier in their prognosis journey. In addition, the company operates Aspira Synergy, a testing platform and cloud service; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.
 CEO
 WEBSITEhttps://aspirawh.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES85

Aspira Women's Health Inc. Frequently Asked Questions


What is the ticker symbol for Aspira Women's Health Inc.? What does AWH stand for in stocks?

AWH is the stock ticker symbol of Aspira Women's Health Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aspira Women's Health Inc. (AWH)?

As of Wed Jun 12 2024, market cap of Aspira Women's Health Inc. is 23.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AWH stock?

You can check AWH's fair value in chart for subscribers.

What is the fair value of AWH stock?

You can check AWH's fair value in chart for subscribers. The fair value of Aspira Women's Health Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aspira Women's Health Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AWH so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aspira Women's Health Inc. a good stock to buy?

The fair value guage provides a quick view whether AWH is over valued or under valued. Whether Aspira Women's Health Inc. is cheap or expensive depends on the assumptions which impact Aspira Women's Health Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AWH.

What is Aspira Women's Health Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, AWH's PE ratio (Price to Earnings) is -1.57 and Price to Sales (PS) ratio is 2.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AWH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Aspira Women's Health Inc.'s stock?

In the past 10 years, Aspira Women's Health Inc. has provided -0.27 (multiply by 100 for percentage) rate of return.